Obesity Discussions to Take Spotlight at RSSDI 2025; Experts to Delve into Tirzepatide's Dual Agonism in Metabolic Care

The topic of obesity and metabolic disease will take centre stage at the upcoming 53rd Annual Conference of the Research Society for the Study of Diabetes in India (RSSDI 2025), with leading experts set to discuss dual GIP/GLP-1 agonism and Tirzepatide’s emerging role in redefining obesity and Type 2 diabetes care.

The annual conference, scheduled from November 6–9, 2025, at the Lulu Bolgatty International Convention Centre, Grand Hyatt, Kochi, will feature multiple focused sessions delving into advances in early diabetes interventions, metabolic care updates and obesity management; with Tirzepatide expected to dominate discussions among key opinion leaders.

The scientific program will feature a series of dedicated obesity symposiums spread across November 7th and 8th, focusing on dual GIP/GLP-1 agonism, real-world experience, and integration of Tirzepatide into clinical care. The sessions will also explore the clinical transition from randomized controlled trials to practice, strategies for optimizing weight loss, and early Indian experiences with Tirzepatide in people with obesity (PwO) and Type 2 diabetes (PwT2D).

The discussions on obesity management will begin on November 7 with the session titled “Dual Agonism – The New Frontier in Obesity Management,” moderated by Dr. Vimal MV. The session will highlight the evolving science behind dual GIP and GLP-1 receptor agonism and its potential to redefine obesity treatment outcomes. Dr. Nihal Thomas will speak on “Dual Path to Success: Tirzepatide in Focus,” followed by Dr. Mohit Bhandari elaborating on “Optimizing Weight Loss: The Science of Weight Loss and Regain.” Dr. JJ Mukherjee will share practical insights through “Clinician’s Guide to Initiating Tirzepatide,” and the session will conclude with an interactive panel discussion.

On November 8, the focus will shift to “Breaking Barriers in Obesity Care with Tirzepatide” moderated by Dr. Puneet Saxena. The session will bring together key thought leaders to discuss clinical approaches and practical challenges in managing obesity. Dr. Krishna Seshadri will present “Unraveling Obesity: The What, Why and How,” followed by Dr. Shashank Joshi, who will shed light on “Redefining Obesity Care with Tirzepatide.” Dr. Ashu Rastogi will then deep dive into “From Trials to Treatment: Integrating Tirzepatide into Clinical Practice.”

The day will continue with another symposium, “Real-World Evidence and Local Experience on Tirzepatide,” chaired by Dr. Arpandev Bhattacharyya. This session will highlight the growing real-world experience with Tirzepatide in India. Dr. Manoj Chawla will discuss “From RCTs to Real-World Evidence,” while Dr. AG Unnikrishnan and Dr. Om Lakhani will share “Early Indian Experience on Tirzepatide” in people with obesity and those with Type 2 diabetes, respectively.

The discussions will conclude on November 9 with a T2D-focused symposium titled “SURPASSing Expectations: Early Management and Dual Agonism in Indian Diabetes Care.” Moderated by Dr. Ajay Kumar, the session will feature Dr. Sudhir Bhandari presenting on “Importance of Early Holistic Management in Type 2 Diabetes,” followed by Dr. Anant Nigam sharing insights from SURPASS 2: Paving the Way to HbA1c and Weight Benefits. Dr. Dheeraj Kapoor will showcase “Early Experience with Tirzepatide in Indian Setting: Patient Cases,” culminating in a fireside chat on “Why Dual Agonism is the Next Frontier in Metabolic Care.”

With 1 out of 7 Indians being overweight¹, staying abreast of the latest therapeutic options has become crucial for clinicians. The introduction of novel pharmacological agents such as Tirzepatide, with its dual GIP and GLP-1 receptor agonism, represents an advancement in the medical management of obesity and Type 2 diabetes. These sessions aim to reinforce the clinical importance of evidence-based, early intervention and the need for physicians to remain updated on new-generation therapies that could offer superior gluco-metabolic and weight outcomes and being made aware about common adverse events seen with this class of drugs which is at par with GLP 1 RAs that are approved in India. By fostering dialogue among experts and highlighting real-world experiences, the discussions are expected to enhance clinical understanding and patient-centered decision-making in metabolic care.

The RSSDI Annual Conference is one of India's largest scientific platforms dedicated to diabetes and metabolic research. The 2025 edition, to be held in Kochi, will feature comprehensive symposia, workshops, and expert dialogues shaping the future of diabetes and metabolic health.

Reference:

• Vennu V, Abdulrahman TA, Bindawas SM. The Prevalence of Overweight, Obesity, Hypertension, and Diabetes in India: Analysis of the 2015-2016 National Family Health Survey. Int J Environ Res Public Health. 2019 Oct 18;16(20):3987. doi: 10.3390/ijerph16203987. PMID: 31635366; PMCID: PMC6843936. https://pubmed.ncbi.nlm.nih.gov/31635366/

For Tirzepatide Prescribing information, please click here: https://image.mc.lilly.com/lib/fe9312747462077971/m/1/0e04e051-5fa2-445b-850d-4f09ef66d35e.pdf. Additional information is available on request

Disclaimer: This material (including any link) is intended solely for the use of the recipient(s) and may contain confidential information. Any unauthorized review, use, disclosure, copying, or distribution is strictly prohibited. If you are not the intended recipient, please notify the sender immediately and destroy all copies of the material. The information provided in this section is intended solely for the use of registered medical practitioner. This material is being provided to healthcare professionals only for their guidance and use. Nothing on this material should be construed as giving medical advice or making recommendations regarding any health-related decision or action.

Tirzepatide is a prescription medication, to be sold by retail under prescription of endocrinologists and internal medicine specialists only.

For further Information about Lilly and Lilly products please contact us at the below address: Plot 92, Sector 32 Gurgaon, Haryana, 122001, India Ph.: +91-124-4753000/01 | www.lillyindia.co.in For adverse events and safety reporting, please reach out to: mailbox_in gps@lilly.com. For any additional information related to Lilly products, please reach out to: queries_in-medinfo@lilly.com

PP-TR-IN-0849 | 29th Oct 2025

© 2025 Eli Lilly and Company. All Rights Reserved.